NO794044L - PROCEDURE FOR PREPARING INCLUSION COMPLEXES OF ALLYCIN WITH CYCLODEXTRINES - Google Patents

PROCEDURE FOR PREPARING INCLUSION COMPLEXES OF ALLYCIN WITH CYCLODEXTRINES

Info

Publication number
NO794044L
NO794044L NO794044A NO794044A NO794044L NO 794044 L NO794044 L NO 794044L NO 794044 A NO794044 A NO 794044A NO 794044 A NO794044 A NO 794044A NO 794044 L NO794044 L NO 794044L
Authority
NO
Norway
Prior art keywords
cyclodextrin
allycin
inclusion complex
mixture
inclusion
Prior art date
Application number
NO794044A
Other languages
Norwegian (no)
Inventor
Jozsef Szejtli
Lajos Szente
Gabor Kulcsar
Gyoergy Koermoeczy
Original Assignee
Chinoin Gyogyszer Es Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyszer Es Vegyeszet filed Critical Chinoin Gyogyszer Es Vegyeszet
Publication of NO794044L publication Critical patent/NO794044L/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Description

Fremgangsmåte ved fremstilling av inklusjonskomplekser av allycin med cyclodextriner Procedure for the production of inclusion complexes of allycin with cyclodextrins

Foreliggende oppfinnelse angår inklusjonskomplekser av allycin med cyclodextriner, fremstilling av disse og farma-søytiske komposisjoner inneholdende dem. The present invention relates to inclusion complexes of allicin with cyclodextrins, their production and pharmaceutical compositions containing them.

Hvitløk (Allium sativum L.) olje omfatter forskjellige svovelholdige komponenter. I tillegg til hovedkomponen-ten diallyldisulfid, inneholder hvitolje diallyltrisulfid, diallyltetrasulfid, dipropyldisulfid, propylallyldisulfid, di-methyldisulfid og allyin. Garlic (Allium sativum L.) oil comprises various sulfur-containing components. In addition to the main component diallyl disulfide, white oil contains diallyl trisulfide, diallyl tetrasulfide, dipropyl disulfide, propylallyl disulfide, dimethyl disulfide and allyin.

Allyin er kjemisk (+)-S-allyl-L-cisteinsulfoxyd [Heiv. Chim. Acta, 21'189 (1948)], og kan omdannes enzymatisk til allycin, dvs. allylthiosulfinsyreallylester [J.A. Chem. Soc, 66, 1950)]. Den sistnevnte forbindelse er en farveløs, ustabil væske med en meget utiltrekkende duft, dens vannløse-lighet er 2,5 %. Allycin er et kraftig antibakterielt middel, og kan lett fremstilles ved flere metoder kjent innen faget Allyin is chemically (+)-S-allyl-L-cysteine sulfoxide [Heiv. Chim. Acta, 21'189 (1948)], and can be enzymatically converted to allicin, i.e. allylthiosulfinic acid allyl ester [J.A. Chem. Soc, 66, 1950)]. The latter compound is a colourless, unstable liquid with a very unattractive smell, its water solubility is 2.5%. Allycin is a powerful antibacterial agent, and can be easily produced by several methods known in the art

[se for eksempel J.Am. Chem. Soc. 66_, 1950 (1944)] .[see, for example, J. Am. Chem. Soc. 66_, 1950 (1944)] .

I vandige og ikke-vandige løsninger såvel som i form av dets faste preparater, spaltes allycin i løpet av ca. 2 da-ger ved romtemperatur og i en inaktiv forbindelse. In aqueous and non-aqueous solutions as well as in the form of its solid preparations, allycin breaks down within approx. 2 days at room temperature and in an inactive compound.

Ifølge foreliggende oppfinnelse tilveiebringes et inklusjonskompleks av allycin med et cyclodextrin. Dette kompleks erholdes i en stabil, krystallinsk form, og kan anvendes som aktiv bestanddel i farmasøytiske komposisjoner med antimikrobiell og/eller fungistatisk aktivitet. According to the present invention, an inclusion complex of allycin with a cyclodextrin is provided. This complex is obtained in a stable, crystalline form, and can be used as an active ingredient in pharmaceutical compositions with antimicrobial and/or fungistatic activity.

Cyclodextriner er cycliske molekyler bestående avCyclodextrins are cyclic molecules consisting of

6, 7 eller 8 glucopyranoséenheter som danner a-1,4-glucoseen-heter. Strukturelt er dissekarakterisert vedet spesialarran-gement av hydroxylgruppene. Alle de sekundære hydroxylgrupper er anbragt på kanten av ringen, mens alle de primære hydroxylgrupper er anbragt på den andre kant av ringen. Derfor er' den ytre overflate av ringen hovedsakelig hydrofob som sikrer at cyclodextrinene er vannløselige. På den annen side har den indre overflate av ringene en hydrofob karakter da det i denne del av molekylet bare finnes hydrogenatomer og glycosidiske oxygenbroer. Hvis molekyler som er mindre polare enn vann og hvis form og størrelse muliggjør penetrering av disse i den hule innside av cyclodextrinene, tilsettes til en vandig løs-ning av cyclodextriner, dannes et cyclodextrininklusjonskom-pleks selv i en vandig løsning. Ringen bestående av 6 gluco- 6, 7 or 8 glucopyranose units forming α-1,4-glucose units. Structurally, these are characterized by the special arrangement of the hydroxyl groups. All the secondary hydroxyl groups are placed on the edge of the ring, while all the primary hydroxyl groups are placed on the other edge of the ring. Therefore, the outer surface of the ring is mainly hydrophobic which ensures that the cyclodextrins are water soluble. On the other hand, the inner surface of the rings has a hydrophobic character as in this part of the molecule there are only hydrogen atoms and glycosidic oxygen bridges. If molecules that are less polar than water and whose shape and size enable their penetration into the hollow interior of the cyclodextrins are added to an aqueous solution of cyclodextrins, a cyclodextrin inclusion complex is formed even in an aqueous solution. The ring consisting of 6 gluco-

pyranoseenheter kalles a-cyclode' trin, ringen bestående av 7 enheter kalles 3_cyclodextrin og ringen med 8 glucopyranose-enheter kalles ycyclodextrin. pyranose units are called a-cyclode' trin, the ring consisting of 7 units is called 3_cyclodextrin and the ring with 8 glucopyranose units is called ycyclodextrin.

Ifølge oppfinnelsen fremstilles inklusjonskomplekser av allycin med cyclod extriner ved at en løsning av allycin i et. vannblandbart løsningsmiddel bringes i kontakt med en vandig løsning av a-, (3- eller ycyclodextrin eller en blanding av hvilke som helst av disse under utelukkelse av luft, og isole-ring av det dannede kompleks fra løsningen, om ønsket etter eliminering av løsningsmidlet fra blandingen hensiktsmessig ved lyofilisering eller krystallisering ved lav temperatur. According to the invention, inclusion complexes of allycin with cyclodextrins are produced by a solution of allycin in a water-miscible solvent is contacted with an aqueous solution of α-, (3-) or γ-cyclodextrin or a mixture of any of these under the exclusion of air, and isolating the complex formed from the solution, if desired after elimination of the solvent from the mixture conveniently by lyophilization or crystallization at low temperature.

Ifølge en foretrukket utførelsesform av prosessen blandes løsningene ved forhøyet temperatur, fortrinnsvis ved 40 - 70° C. Det dannede inklusjonskompleks er mindre løselig i modervæsken enn forbindelsene det fremstilles fra, og utfel-les derfor i visse tilfeller fra modervæsken spontant. Utfel-lingen kan aktiveres ved avkjøling av modervæsken, fortrinnsvis til en temperatur på 0 - 5° C. Alternativt kan inklusjonskomplekset separeres ved lyofilisering av modervæsken. According to a preferred embodiment of the process, the solutions are mixed at an elevated temperature, preferably at 40 - 70° C. The inclusion complex formed is less soluble in the mother liquor than the compounds from which it is produced, and is therefore precipitated from the mother liquor spontaneously in certain cases. The precipitation can be activated by cooling the mother liquor, preferably to a temperature of 0 - 5° C. Alternatively, the inclusion complex can be separated by lyophilization of the mother liquor.

Selv om a-, (3- og ycyclodextrin og eventuelt blan-dinger derav er like egnet for formålet, foretrekkes (3-cyclodextrin. Although α-, β-, β- and β-cyclodextrin and possibly mixtures thereof are equally suitable for the purpose, β-cyclodextrin is preferred.

Allycin løses i vannblandbare løsningsmidler. For dette formål anvendes fortrinnsvis lavere alkanoler og ketoner, men også andre vann-blandbare løsningsmidler såvel som blan-dinger av to eller flere av disse kan anvendes. Allycin løses fortrinnsvis i ethanol. Allycin dissolves in water-miscible solvents. For this purpose, lower alkanols and ketones are preferably used, but other water-miscible solvents as well as mixtures of two or more of these can also be used. Allycin is preferably dissolved in ethanol.

De fysiologisk aktive inklusjonskomplekser fremstilt som ovenfor beskrevet, kan overføres til konvensjonelle farma-søytiske komposisjoner på i og foe seg kjent måte, med formu-lering med en farmasøytisk akseptabel bærer eller exipient. Disse komposisjoner omfatter således inklusjonskompleksene ifølge oppfinnelsen i forbindelse med konvensjonelle exipien-ter, fortynningsmidler.og/eller andre additiver, og kan administreres som tabletter, kapsler, dragéer, suspensjoner, emulsjoner, løsninger, pulvere og/eller forstøvningsmidler. The physiologically active inclusion complexes produced as described above can be transferred to conventional pharmaceutical compositions in a known manner, with formulation with a pharmaceutically acceptable carrier or excipient. These compositions thus comprise the inclusion complexes according to the invention in connection with conventional excipients, diluents and/or other additives, and can be administered as tablets, capsules, dragees, suspensions, emulsions, solutions, powders and/or nebulizers.

Oppfinnelsen illustreres ytterligere i de etterføl-gende eksempler. The invention is further illustrated in the following examples.

Eksempel 1Example 1

10 g 3-cyclodextrin (vanninnhold: 11,4 %) ble løst10 g of 3-cyclodextrin (water content: 11.4%) was dissolved

i 180 ml vann ved 50° C under kontinuerlig omrøring mens nitro-gengass ble boblet gjennom løsningen. 1,45 g allycin ble løst i 5 ml 96 % ethanol, og den erholdte løsning ble langsomt til-satt til den vandige løsning av [3-cyclodextrin. Blandingen ble avkjølt til romtemperatur i løpet av 4 timer med en kon-stant hastighet og holdt ved 0° C i 16 timer. Det utfelte ■ faste materiale ble filtrert fra og lufttørket, under dannelse av 11,02 g av et hvitt mikrokrystallinsk materiale som hadde en svak hvitløkduft. Ifølge gasskromatografi inneholder produktet 10,12 % allycin. Utbytte beregnet for cyclodexrrin: 99,1 % in 180 ml of water at 50° C. with continuous stirring while nitrogen gas was bubbled through the solution. 1.45 g of allicin was dissolved in 5 ml of 96% ethanol, and the resulting solution was slowly added to the aqueous solution of [3-cyclodextrin. The mixture was cooled to room temperature over 4 hours at a constant rate and held at 0°C for 16 hours. The precipitated solid was filtered off and air-dried to yield 11.02 g of a white microcrystalline material having a faint garlic odor. According to gas chromatography, the product contains 10.12% allicin. Yield calculated for cyclodextrin: 99.1%

Utbytte beregnet for allycin: 76,5 %Yield calculated for allycin: 76.5%

Allycin er blitt fremstilt syntetisk etter den metode som er beskrevet i J.Am. Chem. Soc. 6_6 , 1950 (1944). Allycin has been produced synthetically according to the method described in J. Am. Chem. Soc. 6_6 , 1950 (1944).

Produktet har følgende fysikalske karakteristika: Kornstørrelse: 8-11 mikrometer The product has the following physical characteristics: Grain size: 8-11 micrometres

Løselighet i vann: 0,82 g/100 ml ved 25° CSolubility in water: 0.82 g/100 ml at 25° C

Løselighet i ethanol: 0,080 g/100 ml ved 25° C Inklusjonskomplekset er ubegrenset løselig i dimethylformamid og dimethylsulfoxyd. Solubility in ethanol: 0.080 g/100 ml at 25° C. The inclusion complex is infinitely soluble in dimethylformamide and dimethylsulfoxide.

Tynnskiktskromatografi utført på en kieselgel G-plate (Merck) med kloroform gir følgende resultater: Rf = 0,33 (allycin) og Rf = 0,89 (diallyldisulfid). Thin layer chromatography performed on a silica gel G plate (Merck) with chloroform gives the following results: Rf = 0.33 (allycin) and Rf = 0.89 (diallyl disulfide).

Fordelingskromatografi ble utført .med en 5:5:1 blanding av carbontetraklorid, methanol og vann og gir følgen-de resultater: Rf = 0,21 (allycin) og Rf = 0,87 (diallyldisulfid). Kromatogrammer ble fremkalt i joddamp eller med en 1:1 blanding av en 2 %-ig FeCl3og 1 %-ig I<3 [Fe (CN) g]-reaktant. Partition chromatography was carried out with a 5:5:1 mixture of carbon tetrachloride, methanol and water and gives the following results: Rf = 0.21 (allycin) and Rf = 0.87 (diallyl disulphide). Chromatograms were developed in iodine vapor or with a 1:1 mixture of a 2% FeCl3 and 1% I<3 [Fe (CN) g] reactant.

Den aktive bestanddels konsentrasjon av produktet bestemmes fortrinnsvis ved gasskromatografi på en kolonne. The active ingredient concentration of the product is preferably determined by gas chromatography on a column.

Som løsningsmiddel anvendes diethylether, og temperaturen he-ves fra en begynnelsesverdi på 80° C i en hastighet på 10°C/ min. Injektortemperatur: 250° C, detektortemperatur: 300° C (flammionisering). Bærergass: nitrogen, strømningshastighet: 21 ml/min. Diethyl ether is used as solvent, and the temperature is raised from an initial value of 80°C at a rate of 10°C/min. Injector temperature: 250° C, detector temperature: 300° C (flame ionization). Carrier gas: nitrogen, flow rate: 21 ml/min.

RT-verdier: 3,13 (diallyldisulfid)RT values: 3.13 (diallyl disulfide)

5,83 (allycin)5.83 (allycin)

8,51 og 8,69 (ukjente forbindelser med en høyere molekylvekt, sannsynligvis tri- og polysulfider). 8.51 and 8.69 (unknown compounds with a higher molecular weight, probably tri- and polysulfides).

Inklusjonskomplekset av allycin har en RT-verdi på 5,80 under de ovenfor angitte betingelser. The inclusion complex of allycin has an RT value of 5.80 under the above conditions.

Ved røntgendiffraksjonsanalyse av et pulver av 3-cyclodextrin og av et inklusjonskompleks av 3-cyclodextrin og allycin, erholdes etter krystallisering utført under samme betingelser, følgende karakteristiske refleksjonstopper: In X-ray diffraction analysis of a powder of 3-cyclodextrin and of an inclusion complex of 3-cyclodextrin and allicin, after crystallization carried out under the same conditions, the following characteristic reflection peaks are obtained:

Eksempel 2 Example 2

Prosedyren beskrevet i eksempel 1 ble gjentatt, men det krystallinske inklusjonskompleks ble fraskilt fra løsnin-gen ved frysetørking. Det lyofiliserte produkt er et finopp-delt kornaktig materiale, og har bare en svak, knapt luktbar hvitløkduft da det bare er en meget liten mengde av allycin som adsorberes på overflaten av komplekset ved anvendelse av denne teknikk. The procedure described in Example 1 was repeated, but the crystalline inclusion complex was separated from the solution by freeze-drying. The lyophilized product is a finely divided granular material, and has only a faint, barely perceptible garlic odor as only a very small amount of allicin is adsorbed on the surface of the complex using this technique.

Ifølge litteraturdata [Oyo Yakuri 10, 449 (1975)] bevirker. (3-cyclodextrin når den administreres til rotter i en daglig dose på 1,6 g/kg i 6 måneder, ingen toksiske bivirk-ninger . According to literature data [Oyo Yakuri 10, 449 (1975)] effects. (3-cyclodextrin when administered to rats in a daily dose of 1.6 g/kg for 6 months, no toxic side effects.

LDj-q for allycin i rotter: 0,6 g/kg [Heiv. Chim. Acta 31, .189 (1948) ] . LDj-q for allycin in rats: 0.6 g/kg [Heiv. Chim. Acta 31, .189 (1948) ] .

Mikrobiologiske testerMicrobiological tests

Mikrobiologiske tester ble utført med løsninger av allycin og inklusjonskomplekser av allycin med 3_cyclodextrin, i en blanding av ethanol, methanol og "Tween 80". Inklusjonskomplekser av allycin med (B-cyclodextrin ble også testet på den måte at de ble oppløst i dimethylsulfoxyd og den erholdte løsning ble fortynnet med methanol til den ønskede konsentrasjon. De samme.resultater ble erholdt som med den første løs-ningsmiddelblanding. Den observasjon at noe høyere konsentra-sjoner er nødvendig for å oppnå de samme resultater når allycin administreres i form av dets inklusjonskompleks enn i det tilfelle allycin administreres alene, skyldes det faktum at en del av den aktive bestanddel er til stede som et kompleks selv i løsningene. Stabilitetsforsøk viste at inklusjonskomplekser av allycin har en øket stabilitet som muliggjør at disse er effektive i lengre tid. Microbiological tests were carried out with solutions of allycin and inclusion complexes of allycin with 3_cyclodextrin, in a mixture of ethanol, methanol and "Tween 80". Inclusion complexes of allycin with (B-cyclodextrin) were also tested in such a way that they were dissolved in dimethylsulfoxide and the resulting solution was diluted with methanol to the desired concentration. The same results were obtained as with the first solvent mixture. The observation that somewhat higher concentrations are required to achieve the same results when allicin is administered in the form of its inclusion complex than when allicin is administered alone, due to the fact that part of the active ingredient is present as a complex even in the solutions. showed that inclusion complexes of allycin have an increased stability which enables them to be effective for a longer time.

Antibakteriell aktivitet er illustrert i tabell I - IV hvor følgende forkortelser anvendes: Antibacterial activity is illustrated in Tables I - IV where the following abbreviations are used:

CCM: Czechoslovak Collection of MicroorganismsCCM: Czechoslovak Collection of Microorganisms

DSM: Deutsche Sammlung flir MikroorganismenDSM: Deutsche Sammlung flir Mikroorganismen

ATCC: American Type Culture CollectionATCC: American Type Culture Collection

Tester ble vurdert under anvendelse av følgende skala: Tests were rated using the following scale:

0 = ingen vekst (total inhibering)0 = no growth (total inhibition)

+ = meget svak vekst+ = very weak growth

+ = svak vekst+ = weak growth

++ = middels vekst++ = medium growth

+++ = sterk vekst (ingen inhibering) +++ = strong growth (no inhibition)

Antifungal aktivitet er illustrert ved de data som er angitt i Tabell V - X, hvor følgende ytterligere forkortelser anvendes: CBS = Cantralbureau voor Schimmelcultures, Båar, Antifungal activity is illustrated by the data indicated in Tables V - X, where the following additional abbreviations are used: CBS = Cantralbureau voor Schimmelcultures, Båar,

NetherlandNetherlands

OKI = Orszågos Kozegészségiigyi Intézet, Budapest OKI = Orszågos Kozegészségiigyi Intézet, Budapest

Eksempel 3 Example 3

Tablett inneholdende 150 mg allycin-cyclodextrin-kompleks Tablet containing 150 mg of allycin-cyclodextrin complex

Tablettene fremstilles på kjent måte. Blandingen inneholdende de ovenfor angitte bestanddeler granuleres tre etterfølgende ganger før omdannelse til tabletter. The tablets are produced in a known manner. The mixture containing the above-mentioned ingredients is granulated three consecutive times before being transformed into tablets.

Eksempel 4Example 4

Enteroløselige dragéerEnteric-soluble dragees

Tabletter fremstilt ifølge eksempel 3 ble overført til belagte.enteroløselige dragéer. Belegget kan om ønsket også inneholde forskjellige pigmenter med farver som indike-rer konsentrasjonen av den aktive bestanddel. Tablets prepared according to Example 3 were transferred to coated enteric dragees. If desired, the coating can also contain different pigments with colors that indicate the concentration of the active ingredient.

Eksempel 5Example 5

En homogen pulverblanding ble fremstilt på kjent måte . A homogeneous powder mixture was prepared in a known manner.

Blandingen ble fylt i strøbokser. The mixture was filled into litter boxes.

Claims (10)

1. Inklusjonskompleks av allycin med et cyclodextrin.1. Inclusion complex of allycin with a cyclodextrin. 2. Inklusjonskompleks ifølge krav 1, karakterisert ved at cyclodextrinet er a-cyclodextrin.2. Inclusion complex according to claim 1, characterized in that the cyclodextrin is α-cyclodextrin. 3. Inklus jonskompleks ifølge krav 1,. karakterisert ved at cyclodextrinet er 3-cyclodextrin.3. Including ion complex according to claim 1. characterized in that the cyclodextrin is 3-cyclodextrin. 4. Inklusjonskompleks ifølge krav 1, karakterisert ved at cyclodextrinet er ycyclodextrin.4. Inclusion complex according to claim 1, characterized in that the cyclodextrin is ycyclodextrin. 5. Inklusjonskompleks ifølge krav 1, karakterisert ved at cyclodextrinet er en blanding av to eller flere av a-, 3- og Y-cyclodextriner.5. Inclusion complex according to claim 1, characterized in that the cyclodextrin is a mixture of two or more of α-, 3- and Y-cyclodextrins. 6. Fremgangsmåte for fremstilling av et inklusjonskompleks ifølge hvilket som helst av de foregående krav, karakterisert ved at en vandig løsning av a-, (3-eller y-cyclodextrin eller en blanding av hvilke som helst av disse, bringes i kontakt med en løsning av allycin i et vannblandbart løsningsmiddel under utelukkelse av luft, og at allycin-cyclodextrininklus jonskornplekset isoleres .6. Process for producing an inclusion complex according to any one of the preceding claims, characterized in that an aqueous solution of α-, (3- or γ-cyclodextrin or a mixture of any of these is brought into contact with a solution of allycin in a water-miscible solvent under the exclusion of air, and that the allycin-cyclodextrin inclusion ion grain complex is isolated. 7. Fremgangsmåte ifølge krav 6, karakteri- , sert ved at løsningen av cyclodextrin og allycin blandes ved 40 - 70° C, hvorpå reaksjonsblandingen avkjøles til 0 - 5° C.7. Method according to claim 6, characterized in that the solution of cyclodextrin and allycin is mixed at 40 - 70° C, after which the reaction mixture is cooled to 0 - 5° C. 8. ' Fremgangsmåte ifølge hvilke som helst av kravene 6 og 7, karakterisert ved at det som vannblandbart løsningsmiddel anvendes lavere alkanoler, fortrinnsvis ethanol, eller ketoner.8. Method according to any one of claims 6 and 7, characterized in that lower alkanols, preferably ethanol, or ketones are used as water-miscible solvent. 9. Farmasøytisk komposisjon med antimikrobiell og/ eller fungistatisk aktivitet, omfattende et inklusjonskompleks ifølge hvilke som helst av kravene 1 - 7, og en farmasøytisk akseptabel bærer eller excipient.9. Pharmaceutical composition with antimicrobial and/or fungistatic activity, comprising an inclusion complex according to any one of claims 1 - 7, and a pharmaceutically acceptable carrier or excipient. 10. Fremgangsmåte for fremstilling av en farmasøytisk komposisjon med antimikrobiell og/eller fungistatisk aktivitet, karakterisert ved at et inklusjonskompleks av allycin med et a-, 3- eller y-cyclodextrin eller med en blanding av hvilke som helst av disse, blandes med konvensjonelle, farmasøytisk akseptable bærere, excipienter og/eller andre additiver, og at .den erholdte komposisjon formuleres i form av tabletter, kapsler, dragéer, suspensjoner, emulsjoner, løsninger, pulvere og/eller spray.10. Process for the production of a pharmaceutical composition with antimicrobial and/or fungistatic activity, characterized in that an inclusion complex of allicin with an α-, 3- or γ-cyclodextrin or with a mixture of any of these, is mixed with conventional, pharmaceutically acceptable carriers, excipients and/or other additives, and that the resulting composition is formulated in the form of tablets, capsules, dragees, suspensions, emulsions, solutions, powders and/or sprays.
NO794044A 1978-12-12 1979-12-11 PROCEDURE FOR PREPARING INCLUSION COMPLEXES OF ALLYCIN WITH CYCLODEXTRINES NO794044L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU78CI1871A HU177081B (en) 1978-12-12 1978-12-12 Process for preparing the occlusion complex of allicin with cyclodextrin

Publications (1)

Publication Number Publication Date
NO794044L true NO794044L (en) 1980-06-13

Family

ID=10994715

Family Applications (1)

Application Number Title Priority Date Filing Date
NO794044A NO794044L (en) 1978-12-12 1979-12-11 PROCEDURE FOR PREPARING INCLUSION COMPLEXES OF ALLYCIN WITH CYCLODEXTRINES

Country Status (11)

Country Link
JP (1) JPS55115866A (en)
AT (1) AT363492B (en)
CH (1) CH642347A5 (en)
DE (1) DE2948869A1 (en)
DK (1) DK526779A (en)
FR (1) FR2444060A1 (en)
GB (1) GB2061987B (en)
HU (1) HU177081B (en)
NO (1) NO794044L (en)
SU (1) SU938732A3 (en)
YU (1) YU299079A (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU184066B (en) 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
JPS5920230A (en) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト Drug containing piruprophen
FR2550193A1 (en) * 1983-08-05 1985-02-08 Sal Fine Chemicals Internation Inclusion complexes of methyl and allyl trisulphide with cyclodextrins, process for preparing them and pharmaceutical compositions containing them
HU196230B (en) * 1983-12-29 1988-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing water-soluble forms of polyene antibiotics and pharmaceutics comprising such active ingredient and plant protective with antifungal effect
US4678598A (en) * 1985-08-06 1987-07-07 Kao Corporation Liquid shampoo composition
DE3638290A1 (en) * 1986-11-07 1988-05-19 Herbe Wirkstoffe Gmbh Pharmaceutical composition
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
EP0392608B1 (en) * 1989-04-12 1995-06-28 The Procter & Gamble Company Solid consumer product compositions containing small particle cyclodextrin complexes
SE8902235D0 (en) * 1989-06-20 1989-06-20 Haessle Ab NOVEL CYCLODEXTRIN INCLUSION COMPLEXES
CA2013485C (en) * 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
DE4024155C2 (en) * 1990-07-30 1995-12-07 Marcela Dipl Ing Holzhey Use of an "Allicin-Urotropin" product for the area of internal treatment (oral, injections and continuous drip infusions) of humans and animals for fungal diseases
DE4338508A1 (en) * 1993-11-11 1995-05-18 Asta Medica Ag Pharmaceutical preparations containing thioctic acid or dihydroliponic acid in the form of inclusion compounds with cyclodextrins or cyclodextrin derivatives and in the form of granules, chewable or effervescent tablets
DE19500863A1 (en) * 1995-01-13 1996-07-18 Consortium Elektrochem Ind Method of making ajoes
GB0120887D0 (en) * 2001-08-29 2001-10-17 Sahajanand Biotech Private Ltd Local drug delivery system in coronary stents
GB0122793D0 (en) * 2001-09-21 2001-11-14 Stone Island Holdings Ltd Allicin
US20070160725A1 (en) * 2004-03-03 2007-07-12 Mousala, S., L. Use of extracts and compounds of allium-genus plants as preservatives in the food and agri-food industries
GB0422582D0 (en) * 2004-10-11 2004-11-10 Nasaleze Patents Ltd Pharmaceutical compositions
CN107789345B (en) * 2016-09-07 2022-06-28 汤臣倍健股份有限公司 Corrective allicin-cyclodextrin compound and preparation method thereof
CN107802842B (en) * 2016-09-07 2022-04-12 汤臣倍健股份有限公司 Allicin flavouring preparation and its preparation method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3061444A (en) * 1960-10-07 1962-10-30 Gen Foods Corp Inclusion compounds incorporating edible juice constituents
HU174699B (en) * 1977-07-01 1980-03-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing cyclodextrin inclusion complexes of natural and synthetic spices, aromatic and flavoring materials

Also Published As

Publication number Publication date
HU177081B (en) 1981-07-28
AT363492B (en) 1981-08-10
CH642347A5 (en) 1984-04-13
FR2444060A1 (en) 1980-07-11
JPS642105B2 (en) 1989-01-13
YU299079A (en) 1983-06-30
DE2948869A1 (en) 1980-07-03
FR2444060B1 (en) 1984-06-29
DK526779A (en) 1980-06-13
GB2061987A (en) 1981-05-20
DE2948869C2 (en) 1992-07-09
ATA782979A (en) 1981-01-15
GB2061987B (en) 1983-05-18
SU938732A3 (en) 1982-06-23
JPS55115866A (en) 1980-09-06

Similar Documents

Publication Publication Date Title
NO794044L (en) PROCEDURE FOR PREPARING INCLUSION COMPLEXES OF ALLYCIN WITH CYCLODEXTRINES
Del Valle Cyclodextrins and their uses: a review
NO167578B (en) GAMMA CYCLODE EXTRINETS OR MIXED GAMMA CYCLODE EXTRINETER AND PREPARATION OF THEM.
Szejtli The properties and potential uses of cyclodextrin derivatives
US5684169A (en) Cyclodextrin inclusion complex of taxol, and method for its production and its use
EP0470452B1 (en) A method for the production of complexes of long chain polyunsaturated fatty acids and their derivatives, with cyclodextrins, and the resulting complexes
KR20010050028A (en) Cyclodextrin flavor delivery systems
US5741932A (en) Process for preparation of ajoene
CN105461832A (en) Cationic beta-cyclodextrin derivative and preparation method and application thereof
NO300445B1 (en) Complex comprising a pleuromutiline derivative and pharmaceutical composition comprising this complex
FI101385B (en) Process for the preparation of region-specific hydroxyalkylated cyclo dextrins
US6884885B2 (en) Production of cyclodextrin complexes
KR101905937B1 (en) Anthocyanidin complex
US8481716B2 (en) Process for preparing an alpha-lipoic acid/cyclodextrin complex and product prepared
DE69322721T2 (en) Sulphonated compounds from beta-cyclodextrin polymer and medication containing them which inhibits the hyperplasia of the walls of the vessels
Uekama et al. Stabilization of isosorbide 5-mononitrate in solid state by β-cyclodextrin complexation
Pfeffer et al. Cyclolaminarinose. A new biologically active β-(1→ 3) cyclic glucan
WO2013157614A1 (en) Inclusion compound of ketole fatty acid
AU2020219494A8 (en) Photo-protective plant-derived composition
Tomonaga et al. Solubilization and stabilization of lipoic acid trisulfide by creation of various β-cyclodextrin clathrates
US6864246B2 (en) Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae
Rodríguez Mejías et al. Encapsulation of Cynara Cardunculus Guaiane-type Lactones in Fully Organic Nanotubes Enhances Their Phytotoxic Properties
FR2804437A1 (en) PROCESS FOR THE PREPARATION OF MONO-, DI- AND TRICARBOXY CYCLODEXTRINS BY REGIOSELECTIVE OXIDATION IN POSITION 6 OF ALPHA OR BETA OR NATIVE GAMMA-CYCLODEXTRINS
KR102533748B1 (en) Method for producing 1-(2,2-Dimethylpropyl)-cyclopropene as sprayable ethylene antagonist in plants and uses thereof
JP2001081102A (en) Plant growth accelerator